Evidence map›Paper›PMID 42198448›Full record

ArticlePharmaceuticals (Basel, Switzerland)2026

Biological Sex Influences the Pharmacokinetics and Organ Dosimetry of

Xiangsheng Kong, Peishang Li, Zhiqian Wang, Chenchen Cai, Mingjie Zhang, Chunmiao Qu, Chunlei Jin, Hongzhang Zhang, Yeqing Dong, Kai Lv and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiangsheng KongSchool of Pharmacy, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenhe District, Shenyang 110016, China.
Peishang LiMednovo Group Co., Ltd., No. 188 Fuchunjiang Rd., Suzhou New District, Suzhou 215000, China.
Zhiqian WangMednovo Group Co., Ltd., No. 188 Fuchunjiang Rd., Suzhou New District, Suzhou 215000, China.
Chenchen CaiMednovo Group Co., Ltd., No. 188 Fuchunjiang Rd., Suzhou New District, Suzhou 215000, China.
Mingjie ZhangMednovo Group Co., Ltd., No. 188 Fuchunjiang Rd., Suzhou New District, Suzhou 215000, China.
Chunmiao QuMednovo Group Co., Ltd., No. 188 Fuchunjiang Rd., Suzhou New District, Suzhou 215000, China.
Chunlei JinMednovo Group Co., Ltd., No. 188 Fuchunjiang Rd., Suzhou New District, Suzhou 215000, China.
Hongzhang ZhangMednovo Group Co., Ltd., No. 188 Fuchunjiang Rd., Suzhou New District, Suzhou 215000, China.
Yeqing DongInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Kai LvInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.ORCID 0000-0001-6534-3627
Fei HanSchool of Pharmacy, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenhe District, Shenyang 110016, China.

Funding

R&D Center of Mednovo Group Co., Ltd. MDN002
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

177Lu-DOTATATEbiodistributionneuroendocrine tumorspreclinical toxicologysex-dependent pharmacokinetics

Identifiers

PMID42198448
PMCPMC13209772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.